Aytu Bioscience Inc (AYTU) Surpasses Projections as it Receives “Buy Status” Upgrade among Analysts.


Aytu BioScience (NASDAQ:AYTU) has received confirmation from the FDA to begin distribution of its COVID-2019 IgG/IgM Rapid Test throughout the U.S. The test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care. The company expects delivery of its first shipment of 100,000 tests this week.This point-of-care test has been validated in a 126 patient clinical trial and is CE marked, with an above average STR value (meaning a high probability test)

Now, analysts have given Aytu BioScience (NASDAQ:AYTU) a buy-status upgrade, which is rare for a company so soon after multiple offerings. However, the company has surpassed the majority of CoronaVirus related stocks, as it is now in the lead for testing solutions.

“Aytu Bioscience Inc has shown that it can surpass projections by ramping up research and development during the most crucial times, and devoting the most appropriate resources to parts of the company that will actually make an impact on its long-term outlook, which looks like a return to $8.00 price per share trading range is no longer out of the question. “

Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented,

“We are moving as quickly as we can to bring the COVID-19 IgG/IgM Rapid Test to the U.S. professional medical community. With product now in transit to our warehouse in Colorado we’re optimistic that we can have test kits ready for sale in the very near term. In the two short weeks since signing our distribution agreement, we have ordered our first 100,000 tests and have received confirmation from FDA that we may begin distribution. We are optimistic that we’re now just days away from placing these COVID-19 test kits into the hands of healthcare professionals.”

Connecting to recent Stem Cell studies on COVID-19, a new report out shows that Bio-Pharm companies have shifted their focus from CX pathology systems (what has typically been for Coronovirus) to research on the effect of Stem Cell differentiation on the Corona Virus.

Fresh off a successfully reverse merger, and FINRA approved name and ticker change, StemSation International Inc OTCMKTS:STSN just announced entering to DSM industry, and just uploaded a significant amount of filings, which now is reflected by the SEC and OTCmarkets as being Pink current in their reporting requirements. The company is attemping to push from the USA into other markets with their advanced stem cell system (SCS) renewal and repair and the endocannabinoid system (ECS) products.

Since the reverse merger, there is only 1.1 million in the company float, making it a ultra-low float stock. Furthermore, there is now a website launched by the company along with a number of social media sites. With such a small float, a return to the $1.00 trading range is now possible now that the reverse merger is complete, and the company has begun rolling out its new products.

Hard hitting CEO Ray Carter Jr., who was responsible for growing the company StemTech to $65 million, has announced he is now the CEO of StemSation International Inc (OTC:STSN). For over 30 years, Ray has directed growth in both private and public direct selling companies, from start-ups to Fortune 500 firms. His new company, StemSation International Inc (OTC:STSN) has just launched, and is now trading OTC Pink current under the symbol “STSN“.

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Has iBio Pharma (IBIO) Dropped the Ball compared to Aytu Bioscience (AYTU) in the Race to Establish themselves as Leaders in COVID-19 Competition.

There are numerous companies currently that are in a race to establish either shorter testing deltas, as well as a vaccine, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD). For example, so far in the United States, more than 40,000 people have been infected and as community spread rises, health care officials are looking […]

Subscribe US Now